Levine, Joshua A.

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 56

Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1-4

Małecki, M. T., Batterham, R. L., Sattar, N., Levine, J. A., Rodríguez, Á., Bergman, B. K., Wang, H., Ghimpeteanu, G., & Lee, C. J. (2023) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 52

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies

Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 36

Examining the evidence for weight management in individuals with type 2 diabetes

Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 18

Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers

Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 14